We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
Cap. Flow
-$34.2M
Cap. Flow %
-1.55%
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$38M
2
ROIV icon
Roivant Sciences
ROIV
+$28.1M
3
AVTX icon
Avalo Therapeutics
AVTX
+$24.6M
4
RVMD icon
Revolution Medicines
RVMD
+$21.9M
5
INSM icon
Insmed
INSM
+$20.6M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.6M
2
ACLX
Arcellx
ACLX
+$41.7M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.2M
4
TERN
Terns Pharmaceuticals
TERN
+$29.7M
5
APGE icon
Apogee Therapeutics
APGE
+$26.8M

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
2 Miscellaneous 9.21%
3 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RZLT icon
76
Rezolute
RZLT
$437M
$5.2M 0.24%
1,000,000
-547,641
-35% -$2.03M
DTIL icon
77
Precision BioSciences
DTIL
$203M
$5.08M 0.23%
646,576
+48,630
+8% +$342K
COAG
78
Hemab Therapeutics
COAG
$2.07B
$5.07M 0.23%
+138,030
New +$3.81M
VRDN icon
79
Viridian Therapeutics
VRDN
$2.6B
$4.59M 0.21%
250,000
– –
AVBP icon
80
ArriVent BioPharma
AVBP
$1.53B
$4.34M 0.2%
125,000
-50,000
-29% -$1.48M
VRCA icon
81
Verrica Pharmaceuticals
VRCA
$92.1M
$4.33M 0.2%
707,338
– –
CMPS
82
Compass Pathways
CMPS
$1.84B
$4.26M 0.19%
301,183
-807,300
-73% -$8.19M
MBX
83
MBX Biosciences
MBX
$2.96B
$4.14M 0.19%
75,000
-75,000
-50% -$2.62M
RACC
84
Research Alliance Corp III
RACC
$113M
$3.96M 0.18%
+370,000
New +$3.86M
IMVT icon
85
Immunovant
IMVT
$8.08B
$3.85M 0.17%
100,000
– –
AMAN
86
Amanat Acquisition Corp
AMAN
$104M
$3.81M 0.17%
+375,000
New +$3.79M
BHVN icon
87
Biohaven
BHVN
$2.4B
$3.72M 0.17%
+250,000
New +$2.69M
FTH
88
Faeth Therapeutics
FTH
$1.01B
$3.61M 0.16%
+144,404
New +$3.34M
KPTI icon
89
Karyopharm Therapeutics
KPTI
$40.1M
$3.05M 0.14%
312,500
-187,500
-38% -$1.63M
ALEC icon
90
Alector
ALEC
$280M
$3.04M 0.14%
1,510,000
+1,010,000
+202% +$2.16M
SGP
91
SpyGlass Pharma
SGP
$970M
$2.93M 0.13%
131,586
-118,414
-47% -$2.57M
CRNX
92
DELISTED
Crinetics Pharmaceuticals
CRNX
$2.81M 0.13%
75,000
– –
OACCU
93
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$2.75M 0.12%
250,000
– –
JATT
94
JATT II Acquisition Corp
JATT
$95.5M
$2.27M 0.1%
+200,000
New +$2.13M
NMRA icon
95
Neumora Therapeutics
NMRA
$254M
$1.82M 0.08%
+1,070,651
New +$2.04M
AMLX icon
96
Amylyx Pharmaceuticals
AMLX
$3.78B
$1.78M 0.08%
+98,999
New +$1.53M
ANL
97
Adlai Nortye Group ADS
ANL
$950M
$1.77M 0.08%
153,847
-10,901
-7% -$133K
SPRB
98
Spruce Biosciences
SPRB
$166M
$1.62M 0.07%
+30,000
New +$1.68M
SMMT icon
99
CALL
Summit Therapeutics
SMMT
$13.7B
$1.46M 0.07%
+100,000
New +$1.77M
EIKN
100
Eikon Therapeutics
EIKN
$594M
$1.28M 0.06%
+98,001
New +$1M
1 2 3
4
5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
  • Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceuticals, cutting an estimated $34.2M.
  • Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
  • Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
  • Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
  • Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.